Subscribe
Business

ViroPharma turns 2Q loss as Vancocin sales fall

By Washington Examiner
Published
Add Washington Examiner on Google

EXTON, Pa. (AP) — ViroPharma Inc. reported a second-quarter loss as generic competition for the antibiotic Vancocin hurt the drugmaker’s revenue, which tumbled 26 percent.

The Exton, Pa., company said Thursday that Vancocin revenue sank to $15.9 million from $65.2 million because of the introduction of generic vancomycin capsules. Branded drug sales typically drop after a competitor introduces cheaper generic products.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.